21079774

Source:http://linkedlifedata.com/resource/pubmed/id/21079774

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0001483, umls-concept:C0006142, umls-concept:C0007634, umls-concept:C0020969, umls-concept:C0243067, umls-concept:C1518581, umls-concept:C1998548
pubmed:issue	11
pubmed:dateCreated	2010-11-16
pubmed:abstractText	Cancer stem cells/initiating cells (CSC/CIC), are thought to exist as a small population in malignant tissues. They are resistant to conventional cancer treatments and possibly underlie post-treatment relapse. The CIC population can be targeted with capsid modified oncolytic adenoviruses.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/101285081
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD24, http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD44, http://linkedlifedata.com/resource/pubmed/chemical/Interferon Type I, http://linkedlifedata.com/resource/pubmed/chemical/Luminescent Proteins, http://linkedlifedata.com/resource/pubmed/chemical/Myeloid Differentiation Factor 88, http://linkedlifedata.com/resource/pubmed/chemical/STAT1 Transcription Factor, http://linkedlifedata.com/resource/pubmed/chemical/STAT3 Transcription Factor, http://linkedlifedata.com/resource/pubmed/chemical/Suppressor of Cytokine Signaling..., http://linkedlifedata.com/resource/pubmed/chemical/Toll-Like Receptor 2, http://linkedlifedata.com/resource/pubmed/chemical/Toll-Like Receptor 9
pubmed:status	MEDLINE
pubmed:issn	1932-6203
pubmed:author	pubmed-author:AhtiainenLauraL, pubmed-author:CerulloVincenzoV, pubmed-author:DiaconuIuliaI, pubmed-author:EscutenaireSophieS, pubmed-author:HemminkiAkseliA, pubmed-author:JahkolaTiinaT, pubmed-author:KanervaAnnaA, pubmed-author:MirantesCristinaC, pubmed-author:OsterlundPamelaP
pubmed:issnType	Electronic
pubmed:volume	5
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	e13859
pubmed:meshHeading	pubmed-meshheading:21079774-Adenoviridae, pubmed-meshheading:21079774-Antigens, CD24, pubmed-meshheading:21079774-Antigens, CD44, pubmed-meshheading:21079774-Blotting, Western, pubmed-meshheading:21079774-Breast Neoplasms, pubmed-meshheading:21079774-Cell Line, Tumor, pubmed-meshheading:21079774-Female, pubmed-meshheading:21079774-Host-Pathogen Interactions, pubmed-meshheading:21079774-Humans, pubmed-meshheading:21079774-Immune Tolerance, pubmed-meshheading:21079774-Immunity, Innate, pubmed-meshheading:21079774-Interferon Type I, pubmed-meshheading:21079774-Luminescent Proteins, pubmed-meshheading:21079774-Microscopy, Confocal, pubmed-meshheading:21079774-Myeloid Differentiation Factor 88, pubmed-meshheading:21079774-Neoplastic Stem Cells, pubmed-meshheading:21079774-Oncolytic Viruses, pubmed-meshheading:21079774-Reverse Transcriptase Polymerase Chain Reaction, pubmed-meshheading:21079774-STAT1 Transcription Factor, pubmed-meshheading:21079774-STAT3 Transcription Factor, pubmed-meshheading:21079774-Suppressor of Cytokine Signaling Proteins, pubmed-meshheading:21079774-Toll-Like Receptor 2, pubmed-meshheading:21079774-Toll-Like Receptor 9
pubmed:year	2010
pubmed:articleTitle	Defects in innate immunity render breast cancer initiating cells permissive to oncolytic adenovirus.
pubmed:affiliation	Transplantation Laboratory, Cancer Gene Therapy Group, Molecular Cancer Biology Program, Haartman Institute, University of Helsinki, Helsinki, Finland. laura.ahtiainen@helsinki.fi
pubmed:publicationType	Journal Article, Research Support, Non-U.S. Gov't